Azar Hadadi

Azar Hadadi

Auto-generated profile, based on publicly available information

Azar Hadadi

Department of Infectious Disease, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
AHAzar Hadadi
Azar Hadadi
MMMasoud Mortezazadeh
Masoud Mortezazadeh
KKKasra Kolahdouzan
Kasra Kolahdouzan
GAGolbarg Alavian
Golbarg Alavian

31 March 2008 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
AHAzar Hadadi
Azar Hadadi
MRMehrnaz Rasoulinejad
Mehrnaz Rasoulinejad
ZMZohreh Maleki
Zohreh Maleki
MYMasoud Yonesian
Masoud Yonesian
ASAfsaneh Shirani
Afsaneh Shirani
ZKZahra Kourorian
Zahra Kourorian

1 June 2008
Verified
Journal Article
Closed access
AHA. Hadadi
A. Hadadi
SAS. Afhami
S. Afhami
MKM. Karbakhsh
M. Karbakhsh
NEN. Esmailpour
N. Esmailpour

1 February 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MMMahnaz Montazeri
Mahnaz Montazeri
NMNastaran Maghbouli
Nastaran Maghbouli
RJRaika Jamali
Raika Jamali
ASAlireza Sharifi
Alireza Sharifi
MPMarzieh Pazoki
Marzieh Pazoki
AHAzar Hadadi
Azar Hadadi
Background: We aimed to assess the gastrointestinal (GI) manifestations of patients with severe acute respiratory syndrome coronavirus 2 infection and determine factors predicting disease prognosis and severity among patients with GI symptoms. Methods: In this retrospective study, we evaluated laboratory confirmed (by real-time polymerase chain reaction) inpatient cases of coronavirus-associated disease 2019 (COVID-19), referred to Sina hospital, a tertiary educational hospital of Tehran University of Medical Sciences, from March 10 to May 20, 2020. Demographic and clinical characteristics, laboratory data, outcomes and treatment data were extracted and analyzed using SPSS version 20. Results: A total of 611 patients (234 women and 377 men) were included with 155 patients having GI symptoms. The most prevalent reported GI symptom was nausea/vomiting in 115 (18.8%) of patients. A total of 20 patients (3.2%) only had GI symptoms (without respiratory symptoms). There was no statistically significant difference in the clinical outcomes, disease severity, intensive care unit (ICU) admission and mortality between patients with and without GI symptoms. Aspartate Aminotransferase level was associated with 446% increased risk of disease severity (adjusted odds ratio: 5.46, 95% CI: 2.01 to 14.81) (P=0.040) among patients with GI symptoms. Additionally, we found that treatment with antibiotics in addition to mechanical ventilation was associated with increased survival among patients with GI symptoms (Pearson Chi square: 6.22; P value: 0.013). Conclusion: More attention should be paid to patients with only GI symptoms for early patient detection and isolation. Moreover, patients with GI manifestations are not exposed to higher rates of disease severity or mortality.

18 January 2006 in Trials
Verified
Journal Article
Open access
PDF file
BEBehzad Eftekhar
Behzad Eftekhar
MGMohammad Ghodsi
Mohammad Ghodsi
AHAzar Hadadi
Azar Hadadi
MTMousa Taghipoor
Mousa Taghipoor
SSSamira Zabihyan Sigarchi
Samira Zabihyan Sigarchi
EKEbrahim Ketabchi
Ebrahim Ketabchi
Background: The purpose of this study is to compare the efficacy of prophylactic antibiotic for prevention of meningitis in acute traumatic pneumocephalus patients. Methods: In this prospective, randomized controlled clinical trial, 200 selected head injury patients with traumatic pneumocephalus are randomly assigned to receive intravenous antibiotics (2 grams Ceftriaxone twice a day), oral antibiotics (Azithromycin) or placebo for at least 7 days after trauma. The patients will be followed for one month posttrauma. Conclusion: The authors hope that this study helps clarifying the effectiveness and indications of antibiotics in prevention of meningitis in traumatic pneumocephalus after head injury and in specific subgroup of these patients.

1 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
HMHossein Zabihi Mahmoudabadi
Hossein Zabihi Mahmoudabadi
AHAzar Hadadi
Azar Hadadi
Mohammad  Reza FattahiMohammad Reza Fattahi
Mohammad Reza Fattahi
SKSamira Kafan
Samira Kafan
MAMohammad Ashouri
Mohammad Ashouri
RHReza Hajebi
Reza Hajebi
Background. Rectus sheath hematoma is a rare self‐limited presentation that has become a concern in hospitalized COVID‐19 patients receiving anticoagulant therapies. Method. A retrospective multicentric study was conducted in referral hospitals affiliated with the Tehran University of Medical Science, Tehran, Iran, between June and August 2021. Patients with a confirmed diagnosis of COVID‐19 that were complicated with rectus sheath hematoma during hospitalization were included. Median (lower quartile to upper quartile) was used to report the distribution of the results. Result. This study was conducted on nine patients with confirmed COVID‐19 pneumonia, including eight females and one male. The severity of viral pneumonia was above average in eight patients. The median age and median body mass index were 65 (55.5 to 78) years and 29.38 (23.97 to 31.71) kg/m2. The duration of anticoagulant therapy was 10 (6 to 14) days, and the median length of hospital stay was 20 (10 to 23.5) days. Rectus sheath hematoma occurred after a median reduction of 4 (2.7 to 6.6) units in blood hemoglobin. Although 66.7% received ICU care and all of them were under full observation in well‐equipped hospitals, the mortality rate was 55.6%. Conclusion. In summary, increased levels of inflammatory markers such as lactic acid dehydrogenase along with an abrupt decrease in blood hemoglobin in COVID‐19 patients should be considered as predisposing factors for rectus sheath hematoma, especially in patients with moderate to severe COVID‐19 pneumonia under anticoagulant therapy. This complication had been considered a self‐limited condition; however, it seems to be fatal in patients with COVID‐19 pneumonia. Further studies in larger sample sizes should be conducted to find out suitable management for this complication.